Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?


Akyuz F., Cavus B., Iliaz R., Soyer O., Ormeci A., Evirgen S., ...Daha Fazla

European journal of gastroenterology & hepatology, cilt.31, ss.777-780, 2019 (SCI-Expanded, Scopus)